The federal government’s dispute with Harvard University over billions of dollars in research funding is now more than a year old, has produced a major district-court ruling, an active appeal, and a second Justice Department lawsuit — and the procedural fight underway at the U.S. Court of Appeals for the First Circuit has implications that reach well past Harvard. This piece tracks where things actually stand and explains the angle research administrators elsewhere should be watching: not the campus politics, but the jurisdictional argument the government is making about how any university can challenge a federal grant termination at all.
This is an active, fast-moving legal matter. The summary below reflects court filings and reporting available as of this writing, drawn primarily from Harvard University’s own public litigation tracker and contemporaneous coverage. Dollar figures in particular vary across sources because they were reported at different points as new tranches of funding were frozen, terminated, or restored — treat the ranges below as directional, and check Harvard’s own tracker (linked at the end) for current, award-level status.
Timeline: how the dispute got here
- April 2025 — Following weeks of federal pressure over allegations that Harvard had not adequately addressed antisemitism on campus, the administration sent Harvard a letter demanding specific governance, hiring, admissions, and “viewpoint diversity” changes as a condition of continued federal funding. Harvard publicly refused to comply.
- Spring–summer 2025 — Federal agencies issued stop-work orders and then formal termination notices across a large number of Harvard’s federal research grants and contracts. Reporting on the cumulative dollar figure varies by tranche and by date, with figures cited in different accounts ranging from roughly $2.2 billion to nearly $3 billion in frozen or terminated funding by mid-2026.
- September 3, 2025 — U.S. District Judge Allison D. Burroughs (D. Mass.) ruled that the funding freeze and terminations were unlawful, finding violations of the First Amendment and the Administrative Procedure Act. She wrote that the administrative record made it “difficult to conclude anything other than” that the government had used antisemitism as a “smokescreen for a targeted, ideologically-motivated assault” on the university, and ordered the funding restored.
- December 18, 2025 — The Department of Justice announced it would appeal the ruling to the First Circuit.
- March 20, 2026 — DOJ filed a separate, new lawsuit that Harvard has characterized as adding further legal and financial uncertainty for the university’s research enterprise, including at Harvard Medical School.
- April 2026 — The government filed its opening appellate brief, arguing (1) Judge Burroughs lacked jurisdiction to block the cuts, (2) Title VI is not the exclusive mechanism for terminating federal funds over discrimination concerns, and (3) the April 2025 demand letter did not violate the First Amendment. A separate filing argued the dispute should be treated as a contract matter and routed to the U.S. Court of Federal Claims rather than reviewed as agency action in district court.
- May 18, 2026 — Harvard moved to dismiss the government’s March 2026 lawsuit, calling it “another transparent — but equally unlawful — effort to accomplish the ends the Government has long sought.”
As of this writing, the First Circuit appeal remains pending, with no ruling yet from the appellate panel, and Harvard’s motion to dismiss the newer DOJ suit is likewise unresolved.
The jurisdictional argument that matters far beyond Harvard
The most consequential thread in the appeal is not the underlying antisemitism dispute — it’s a procedural argument about which court gets to hear a federal grant-termination challenge, and what remedies that court can offer. The government’s position is that a federal research grant is fundamentally a contract, and that contract disputes over federal awards belong in the U.S. Court of Federal Claims under the Tucker Act, not in a federal district court reviewing agency action under the Administrative Procedure Act.
That distinction is not academic for a research office. The Court of Federal Claims generally cannot hear constitutional claims (like a First Amendment retaliation claim) and, critically, cannot issue injunctive relief — it can only award money damages after the fact. A university whose funding is frozen mid-project cannot use a damages-only forum to get an injunction keeping labs open, staff paid, and clinical trials running while the underlying dispute is litigated. If appellate courts accept the government’s “it’s just a contract” framing for grant terminations generally, it would meaningfully narrow the toolkit any institution — not just Harvard — has for contesting a funding cutoff in real time, regardless of the underlying justification the government offers for the termination.
This is the same jurisdictional question that has surfaced in other 2025–2026 federal-funding litigation, including disputes over NIH and NSF grant terminations more broadly (see CASRAI’s NIH funding cuts in 2026 landscape review and NSF funding cuts and grant-termination litigation pieces). Harvard’s case is the highest-profile test of it, but the outcome of the jurisdictional fight — however it resolves — will shape the procedural options available to any institution facing a grant termination it believes is unlawful or pretextual, not just Harvard’s.
What research administrators elsewhere should take from this
- Know the difference between a stop-work order, a suspension, and a termination. These have distinct procedural and appeal implications under an award’s own terms and, for most federal grants, under the termination grounds set out in 2 CFR 200.340. CASRAI’s NIH grant terminations guide walks through the four permissible grounds and the notice-and-objection process in detail.
- Venue and forum affect available relief, not just outcome. Whether a challenge proceeds as an APA claim in district court or a contract claim in the Court of Federal Claims determines whether an injunction is even on the table — a distinction worth understanding before a dispute arises, not during one.
- Conditions attached to funding via correspondence (rather than the award’s own terms) are now a live legal battleground. Whether a funding agency can condition continued support on demands unrelated to the grant’s scope of work — governance changes, hiring practices, disclosure requirements — is squarely at issue in this case and in the broader 2025–2026 litigation landscape. Research offices fielding similar informal demand letters should treat them as a matter for institutional counsel, not just the sponsored-programs office.
- Track the pattern, not just the headline institution. Harvard’s case is the largest by dollar value and the most litigated, but it sits alongside a broader wave of 2025–2026 federal funding actions across NIH, NSF, and other agencies. Institutions with federal awards should treat the jurisdictional and procedural precedents set here as relevant to their own risk exposure, independent of whether they share Harvard’s specific fact pattern.
Sources and further reading
For current, primary-source status, Harvard maintains its own public litigation tracker, which is the most authoritative and frequently updated source on award-level reinstatement status: Harvard University, Federal Lawsuits — Research Funding. Reporting cited in this piece also draws on coverage from PBS NewsHour, Harvard Magazine, the Boston Globe, and the Harvard Crimson. This page will need to be revisited as the First Circuit appeal and the newer DOJ lawsuit progress; readers relying on this for institutional risk assessment should confirm current status against primary court dockets and Harvard’s own tracker rather than treating any single point-in-time summary as final.
For related CASRAI coverage of the broader 2025–2026 federal research-funding landscape, see the NIH grant terminations: grounds, process, and appeal rights guide, the NIH funding cuts in 2026 landscape review, and NSF funding cuts, grant terminations, and the 2026 litigation landscape.
